



07/22/2021

Vermont Attorney General's Office
109 State Street
Montpelier, VT 05609

AGO.highcostprescriptiondrugs@vermont.gov

To Whom It May Concern:

As required by 18 V.S.A. § 4637(b), Albireo Pharma, Inc. is providing notice of the introduction of a new prescription drug with a Wholesale Acquisition Cost that exceeds the threshold set for a specialty drug under the Medicare Part D program on November 4, 2020. The new product being launched is:

NDC:	Product Trade Name:	WAC:
74528-0020-01	Bylvay 200mcg	\$6,600.00
74528-0040-01	Bylvay 400mcg	\$13,200.00
74528-0060-01	Bylvay 600mcg	\$19,800.00
74528-0120-01	Bylvay 1200mcg	\$39,600.00

Bylvay was approved by the FDA on July 20, 2021, and the estimated date of commercial availability is to be determined.

Sincerely,

Annamarie Lee
Agent for Albireo Pharma, Inc.